Naftopidil dihydrochloride (CAS: 57149-08-3) is a selective alpha1D-adrenoreceptor antagonist, developed by Tanabe Seiyaku for the treatment of various urological disorders, such as benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Alpha1D-adrenoreceptor antagonists act by relaxing smooth muscle in the bladder neck and prostate.
Chemical name: 2-[(2R)-2-[3-(2-Methoxyphenyl)propylamino]propyl]quinoxaline-5,6-diol dihydrochloride
Molecular formula: C20H26N4O3.2HCl
Formula weight: 458.36 g/mol
CAS No: 57149-08-3
Top ten keywords from Google:
Synonyms:
Health benefits of this product: Naftopidil dihydrochloride has been shown to improve urinary flow rate and reduce the severity of LUTS in patients with BPH, either as a monotherapy or in combination with other drugs. It works by selectively blocking alpha1D-adrenoreceptors in the bladder neck and prostate, leading to smooth muscle relaxation and improved urine flow. Additionally, naftopidil dihydrochloride may have potential benefits for sexual function in some patients.
Potential effects: Naftopidil dihydrochloride has demonstrated efficacy in improving urinary flow rate and reducing the severity of LUTS in patients with BPH, either as a monotherapy or in combination with other drugs. It has also been shown to improve erectile function and sexual satisfaction in some patients. Additionally, naftopidil dihydrochloride may have potential benefits for bladder neck obstruction and overactive bladder, although more research is needed in these areas.
Product mechanism: Naftopidil dihydrochloride works by selectively blocking alpha1D-adrenoreceptors in the bladder neck and prostate, leading to smooth muscle relaxation and improved urine flow. Alpha1D-adrenoreceptors are predominantly expressed in the lower urinary tract, and their blockade results in increased blood flow and reduced resistance to urine flow. This mechanism of action does not affect blood pressure or heart rate, making it a useful therapeutic option for patients who cannot tolerate other drugs that affect these parameters.
Safety: Naftopidil dihydrochloride has been evaluated in several clinical trials involving thousands of patients with BPH and LUTS. Overall, it has been well-tolerated, with manageable side effects. The most common adverse events reported were headache, dizziness, and fatigue. More severe side effects, such as hypotension and cardiovascular events, were rare and usually resolved after dose adjustments or discontinuation.
Side effects: Common side effects of naftopidil dihydrochloride include headache, dizziness, and fatigue. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include hypotension and cardiovascular events, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The recommended dose of naftopidil dihydrochloride varies depending on the patient's condition and treatment goals. In clinical trials, doses ranging from 25 to 100 mg have been evaluated, either as a monotherapy or in combination with other drugs. Treatment duration also varies and can range from a few weeks to several months or years, depending on the response and tolerability. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Naftopidil dihydrochloride (CAS: 57149-08-3) is a selective alpha1D-adrenoreceptor antagonist developed by Tanabe Seiyaku for the treatment of various urological disorders, such as BPH and LUTS. Its mechanism of action involves selectively blocking alpha1D-adrenoreceptors in the bladder neck and prostate, leading to smooth muscle relaxation and improved urine flow. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. Further research is needed to determine its full potential and efficacy in different patient populations, including those with bladder neck obstruction and overactive bladder.
